Trial Profile
(Clinical Outcomes and Safety Trial to Investigate Ecallantide's Effect on Reducing Surgical Blood Loss Volume) A Phase 2 Randomized Placebo-controlled Dose-ranging Study in Subjects Exposed to Cardio-pulmonary Bypass During Primary Coronary Artery Bypass Graft Surgery
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Surgical blood loss
- Focus Therapeutic Use
- Acronyms CONSERV-1
- Sponsors Cubist Pharmaceuticals
- 05 Jun 2014 New trial record